Related references
Note: Only part of the references are listed.Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi et al.
NATURE MEDICINE (2022)
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
Yojiro Hashiguchi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Emilie Moati et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type.
Jason Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
Chiara Nicolazzo et al.
CANCERS (2020)
Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
Mohamed Bouchahda et al.
JCO PRECISION ONCOLOGY (2020)
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer
Yu Sunakawa et al.
JCO PRECISION ONCOLOGY (2020)
Clinical utility of circulating tumor DNA for colorectal cancer
Hiroki Osumi et al.
CANCER SCIENCE (2019)
FOLFIRI plus panitumumab as second -line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first -line FOLFOXICAPDX plus bevacizumab-based treatment: Phase II CONVERTIX trial
A. Fernandez Montes et al.
ANNALS OF ONCOLOGY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
Cristina Raimondi et al.
CANCERS (2019)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy
Keishi Sugimachi et al.
BRITISH JOURNAL OF CANCER (2018)
481PPhase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
H Osawa et al.
ANNALS OF ONCOLOGY (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Yasutoshi Kuboki et al.
LANCET ONCOLOGY (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing
Weihua Li et al.
CANCER LETTERS (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
Marta Schirripa et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients
Frank Diehl et al.
GASTROENTEROLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
